Phase 1b/2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer (VIRO-15)

Trial Profile

Phase 1b/2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer (VIRO-15)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs GL ONC1 (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms VIRO-15
  • Sponsors Genelux Corporation
  • Most Recent Events

    • 27 Sep 2017 According to a Genelux Corporation media release, data from this trial exceeded the futility boundary of an equivalent interim analysis for a 2-stage Simon design at the current Phase 2 dose level, supporting the continued development of GL-ONC in this patient population.
    • 27 Sep 2017 According to a Genelux Corporation media release, the first patient has been treated in the Phase 2 portion of this trial. The company is planning to recruit subjects at additional site(s) in the US. Total of 40 patients are planned to enrolled in the trial in two cohorts.
    • 04 Aug 2017 The phase has been changed from 1b to 1b/2,with the addition of efficacy endpoint.Patient number also increases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top